Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nonbismuth Quadruple "Concomitant" Therapy Versus Standard Triple Therapy, Both of the Duration of 10 Days, for First-Line H. Pylori Eradication: A Randomized Trial

Trial Profile

Nonbismuth Quadruple "Concomitant" Therapy Versus Standard Triple Therapy, Both of the Duration of 10 Days, for First-Line H. Pylori Eradication: A Randomized Trial

Completed
Phase of Trial: Phase III

Latest Information Update: 04 May 2014

At a glance

  • Drugs Esomeprazole (Primary) ; Amoxicillin; Clarithromycin; Metronidazole
  • Indications Helicobacter pylori infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Sep 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top